Pharmacoeconomic concepts in antiplatelet therapy: Understanding cost-effectiveness analyses using clopidogrel as an example

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 2, 2008, Pages 107-119

  Weintraub, William S ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Clopidogrel; Cost benefit; Cost utility; Economic burden; Pharmacoeconomics

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG COST; DRUG MECHANISM; DRUG RESEARCH; DRUG UTILIZATION; HEART INFARCTION; HUMAN; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; TERMINOLOGY AS TOPIC; TICLOPIDINE;

EID: 43949089842     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407313151     Document Type: Review

References (44)

1. DiMasi JA, Hansen RW, Grabowski HG The price of innovation: new estimates of drug development costs. J Health Econ. 2003 ; 22: 151-185.
2. Bristol-Myers Squibb-Sanofi Pharmaceuticals Partnership. Plavix (clopidogrel bisulfate tablets): prescribing information; 2006 August.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 ; 352: 1179-1189.
4. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW Methods for the Economic Evaluation of Health Care Programmes. 2 nd ed. Oxford, UK: Oxford University Press ; 1997.
5. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC Preferences for health outcomes. Comparison of assessment methods. Med Decis Making. 1984 ; 4: 315-329.
6. Stone PW, Chapman RH, Sandberg EA, Liljas B., Neumann PJ Measuring costs in cost-utility analyses. Variations in the literature. Int J Technol Assess Health Care. 2000 ; 16: 111-124.
7. McGregor M. Cost-utility analysis: use QALYs only with great caution. CMAJ. 2003 ; 168: 433-434.
8. Hay J., Jackson J., Luce B., Avorn J., Ashraf T. Panel 2: Methodological issues in conducting pharmacoeconomic evaluations-modeling studies. Value Health. 1999 ; 2: 78-81.
9. Drummond M., Sculpher M. Better analysis for better decisions: has pharmacoeconomics come of age ? Pharmacoeconomics. 2006 ; 24: 107-108.
10. Jefferson T., Demicheli V. Quality of economic evaluations in health care. BMJ. 2002 ; 324: 313-314.
11. Neumann PJ The arrival of economic evidence in managed care formulary decisions: the unsolicited request process. Med Care. 2005 ; 43: 27-32.
12. Hill S. Transparency in economic evaluations. Pharmacoeconomics. 2005 ; 23: 967-969.
13. Drummond MF, Jefferson TO Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996 ; 313: 275-283.
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 ; 348: 1329-1339.
15. Mehta SR, Yusuf S., Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358: 527-533.
16. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288: 2411-2420.
17. Yusuf S., Zhao F., Mehta SR, Chrolavicius S., Tognoni G., Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345: 494-502.
18. American Heart Association. Heart disease and stroke statistics: 2006 update. http://www.americanheartassociation.com. Accessed November 14, 2006.
19. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002 ; 346: 1800-1806.
20. Durand-Zaleski I., Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics. 2004 ; 22 (Suppl 4). 19-27.
21. Lyseng-Williamson KA, Plosker GL Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics. 2006 ; 24: 709-726.
22. Mahoney EM, Mehta S., Yuan Y., et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006 ; 151: 219-227.
23. Schleinitz MD, Heidenreich PA A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005 ; 142: 251-259.
24. Weintraub WS, Mahoney EM, Lamy A., et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005 ; 45: 838-845.
25. Coyle D., Lee KM The problem of protocol driven costs in pharmacoeconomic analysis. Pharmacoeconomics. 1998 ; 14: 357-363.
26. Glennie JL, Torrance GW, Baladi JF, et al. The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics. 1999 ; 15: 459-468.
27. Jacobs P., Ohinmaa A., Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics. 2005 ; 23: 143-153.
28. Soto J. Health economic evaluations using decision analytic modeling. Principles and practices-utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care. 2002 ; 18: 94-111.
29. Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics. 2000 ; 17: 443-444.
30. Philips Z., Bojke L., Sculpher M., Claxton K., Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006 ; 24: 355-371.
31. Schulman KA, Lynn LA, Glick HA, Eisenberg JM Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 ; 114: 798-802.
32. Weintraub W., Jonsson B., Bertrand M. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomics. 2004 ; 22 (Suppl 4). 29-41.
33. Mahoney EM, Jurkovitz CT, Chu H., et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002 ; 288: 1851-1858.
34. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation. 2000 ; 101: 366-371.
35. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992 ; 327: 7-13.
36. Johannesson M., Jonsson B., Kjekshus J., Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997 ; 336: 332-336.
37. Tsevat J., Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001 ; 141: 727-734.
38. Drummond M., Torrance G., Mason J. Cost-effectiveness league tables: more harm than good ? Soc Sci Med. 1993 ; 37: 33-40.
39. Mason J., Drummond M., Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ. 1993 ; 306: 570-572.
40. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics. 2004 ; 22 (Suppl 4). 5-10.
41. Ubel PA, Hirth RA, Chernew ME, Fendrick AM What is the price of life and why doesn't it increase at the rate of inflation ? Arch Intern Med. 2003 ; 163: 1637-1641.
42. Beinart SC, Kolm P., Veledar E., et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol. 2005 ; 46: 761-769.
43. Lamy A., Jonsson B., Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil. 2004 ; 11: 460-465.
44. Ringborg A., Lindgren P., Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ. 2005 ; 6: 354-356, 358-362.